PET Scan in Treating Patients With Metastatic Prostate Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any - 120 |
| Updated: | 12/6/2018 |
| Start Date: | January 1997 |
| End Date: | April 2020 |
11C-Methionine and 2-18F-Fluoro-2-Deoxy-D-Glucose PET Imaging in Patients With Progressive Prostate Cancer
RATIONALE: New imaging procedures, such as PET scan, may improve the ability to detect new or
recurrent prostate cancer.
recurrent prostate cancer.
OBJECTIVES:
- Measure the pharmacokinetics, whole body retention of isotope, and biodistribution of
C11-methionine and FDG by PET imaging and serial sampling of blood in men with
progressive prostate cancer.
- Explore metabolism of each PET scan by comparing the sensitivity of C11-methionine or
FDG by PET scanning in androgen independent prostate cancer metastases with the
sensitivity of C11-methionine or FDG in androgen dependent metastases on a site by site
basis.
- Compare C11-methionine and FDG PET scanning to standard of care diagnostic studies which
include the Tc 99m bone scan, computed tomography, and magnetic resonance imaging.
Patients fast for 6 hours prior to PET imaging with the exception of liberal water intake
which is encouraged. A two way catheter is placed in the urinary bladder, and continuous
isotonic saline irrigation is performed throughout scan acquisition to reduce the
interference in imaging lesions in the pelvic lymph nodes and adjacent pelvic bones caused by
radiation excreted in urine held in the bladder.
Each patient receives C11-methionine intravenously. PET imaging begins immediately after
injection for approximately 60 minutes total using standard imaging procedures. Immediately
following the completion of imaging after C11-methionine administration, each patient
receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for
approximately 60 minutes using standard imaging procedures.
- Measure the pharmacokinetics, whole body retention of isotope, and biodistribution of
C11-methionine and FDG by PET imaging and serial sampling of blood in men with
progressive prostate cancer.
- Explore metabolism of each PET scan by comparing the sensitivity of C11-methionine or
FDG by PET scanning in androgen independent prostate cancer metastases with the
sensitivity of C11-methionine or FDG in androgen dependent metastases on a site by site
basis.
- Compare C11-methionine and FDG PET scanning to standard of care diagnostic studies which
include the Tc 99m bone scan, computed tomography, and magnetic resonance imaging.
Patients fast for 6 hours prior to PET imaging with the exception of liberal water intake
which is encouraged. A two way catheter is placed in the urinary bladder, and continuous
isotonic saline irrigation is performed throughout scan acquisition to reduce the
interference in imaging lesions in the pelvic lymph nodes and adjacent pelvic bones caused by
radiation excreted in urine held in the bladder.
Each patient receives C11-methionine intravenously. PET imaging begins immediately after
injection for approximately 60 minutes total using standard imaging procedures. Immediately
following the completion of imaging after C11-methionine administration, each patient
receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for
approximately 60 minutes using standard imaging procedures.
DISEASE CHARACTERISTICS:
- Histologically confirmed prostate adenocarcinoma
- Must have an at least 50% increase in PSA which is sustained for a minimum of 3
observations obtained at least 1 week apart
- Must have development of new lesions on bone scintigraphy or greater than 50% increase
in measurable disease on CT or MRI scan
- Metastatic disease
PATIENT CHARACTERISTICS:
Age:
- Not specified
Performance status:
- Karnofsky greater than 60%
Hematopoietic:
- ANC greater than 1,000/mm^3
- Platelet count greater than 100,000/mm^3
Hepatic:
- Not specified
Renal:
- Not specified
Cardiovascular:
- No clinically significant cardiac disease
Pulmonary:
- No clinically significant pulmonary disease
Other:
- No active infection not controlled by antibiotics
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
